Alzheimer's disease: treatments in discovery and development

被引：143

作者：

Citron, M ^{[1
]}

机构：

[1] Amgen Inc, Dept Neurosci, Thousand Oaks, CA 91320 USA

来源：

NATURE NEUROSCIENCE | 2002年 / 5卷 / Suppl 11期

关键词：

D O I：

10.1038/nn940

中图分类号：

Q189 [神经科学];

学科分类号：

071006 [神经生物学];

摘要：

Alzheimer's disease is the single biggest unmet medical need in neurology. Current drugs are safe, but of limited benefit to most patients. This review discusses the scientific basis and current status of promising disease-modifying therapies in the discovery and development stages. I describe the major targets of anti-amyloid therapy and the main focus of disease modification approaches. In addition, two new potential treatment approaches supported by retrospective epidemiology are outlined.

引用

收藏

页码：1055 / 1057

页数：3

相关论文

共 29 条

[1]

Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease [J].

Bard, F ;

Cannon, C ;

Barbour, R ;

Burke, RL ;

Games, D ;

Grajeda, H ;

Guido, T ;

Hu, K ;

Huang, JP ;

Johnson-Wood, K ;

Khan, K ;

Kholodenko, D ;

Lee, M ;

Lieberburg, I ;

Motter, R ;

Nguyen, M ;

Soriano, F ;

Vasquez, N ;

Weiss, K ;

Welch, B ;

Seubert, P ;

Schenk, D ;

Yednock, T .

NATURE MEDICINE, 2000, 6 (08) :916-919

[2]

The galvanization of β-amyloid in Alzheimer's disease [J].

Bush, AI ;

Tanzi, RE .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (11) :7317-7319

[3]

Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice [J].

Cherny, RA ;

Atwood, CS ;

Xilinas, ME ;

Gray, DN ;

Jones, WD ;

McLean, CA ;

Barnham, KJ ;

Volitakis, I ;

Fraser, FW ;

Kim, YS ;

Huang, XD ;

Goldstein, LE ;

Moir, RD ;

Lim, JT ;

Beyreuther, K ;

Zheng, H ;

Tanzi, RE ;

Masters, CL ;

Bush, AI .

NEURON, 2001, 30 (03) :665-676

[4]

CITRON M, IN PRESS J NEUROSCI

[5]

Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease [J].

DeMattos, RB ;

Bales, KR ;

Cummins, DJ ;

Dodart, JC ;

Paul, SM ;

Holtzman, DM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (15) :8850-8855

[6]

Therapeutic standards in Alzheimer disease [J].

Doody, RS .

ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 1999, 13 :S20-S26

[7]

Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo [J].

Fassbender, K ;

Simons, M ;

Bergmann, C ;

Stroick, M ;

Lütjohann, D ;

Keller, P ;

Runz, H ;

Kühl, S ;

Bertsch, T ;

von Bergmannn, K ;

Hennerici, M ;

Beyreuther, K ;

Hartmann, T .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (10) :5856-5861

[8]

aph-1 and pen-2 are required for notch pathway signaling, γ-secretase cleavage of βAPP, and presenilin protein accumulation [J].

Francis, R ;

McGrath, G ;

Zhang, JH ;

Ruddy, DA ;

Sym, M ;

Apfeld, J ;

Nicoll, M ;

Maxwell, M ;

Hai, B ;

Ellis, MC ;

Parks, AL ;

Xu, W ;

Li, JH ;

Gurney, M ;

Myers, RL ;

Himes, CS ;

Hiebsch, R ;

Ruble, C ;

Nye, JS ;

Curtis, D .

DEVELOPMENTAL CELL, 2002, 3 (01) :85-97

[9]

Cholesterol modulation as an emerging strategy for the treatment of Alzheimer's disease [J].

Golde, TE ;

Eckman, CB .

DRUG DISCOVERY TODAY, 2001, 6 (20) :1049-1055

[10]

AMYLOID DEPOSITION AS THE CENTRAL EVENT IN THE ETIOLOGY OF ALZHEIMERS-DISEASE [J].

HARDY, J ;

ALLSOP, D .

TRENDS IN PHARMACOLOGICAL SCIENCES, 1991, 12 (10) :383-388